| Adjusted odds ratio (95% CI) of therapy received | ||
---|---|---|---|
Therapy received | Polytherapy | High dose | Polytherapy and high dose |
Model size | n = 400 | n = 400 | n = 312 |
Cohort (base: 1st) | 1.81 (1.08–3.02)* | - | 2.14 (1.10–4.17)* |
Gender (base: male) | - | - | - |
Age (year) | - | - | - |
Ethnicity (base: Australian) | - | - | - |
Adm. in last 12 m (base: one or two): | Â | Â | Â |
- three or four | 1.77 (0.87–3.60) | - | 2.28 (0.97–5.35) |
- five or more | 7.52 (2.92–19.4)* | - | 5.30 (1.57–17.8)* |
Hospital stay (day) | ^ | ^ | ^ |
Primary diagn. (base: schizophrenia): | Â | Â | Â |
- bipolar disorder | 0.19 (0.08–0.47)* | - | 0.26 (0.08–0.80)* |
- other psychotic disorder | 0.33 (0.14–0.75)* | - | 0.33 (0.11–1.00) |
- other | 0.40 (0.21–0.76)* | - | 0.40 (0.17–0.91)* |
Comorbid substance use disorder | - | - | - |
Involuntary treatment | 3.95 (2.31–6.77)* | 2.22 (1.34–3.66)* | 3.18 (1.61–6.29)* |
Previous clozapine trial | 5.80 (2.43–13.8)* | 2.19 (1.10–4.38)* | 5.58 (2.04–15.3)* |